Emerging evidence suggests that BCL6B is closely associated with the initiation, progression, and clinical outcomes of multiple malignancies, including hepatocellular carcinoma (HCC), gastric cancer (GC), breast cancer (BC), colorectal cancer (CRC), lung cancer (LC), thyroid cancer (TC), cervical cancer (CC), renal cell carcinoma (RCC), differentiated thyroid carcinoma (DTC), and lymphomas. Here, BCL6B is linked to laryngotracheoesophageal cleft.